{
    "clinical_study": {
        "@rank": "119444", 
        "acronym": "PAH", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: Dose 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Bardoxolone methyl [Dose 1] mg capsules or placebo by mouth once daily x 16 weeks"
            }, 
            {
                "arm_group_label": "Cohort 2: Dose 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Bardoxolone methyl [Dose 2] mg capsules or placebo by mouth once daily x 16 weeks"
            }, 
            {
                "arm_group_label": "Cohort 3: Dose 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Bardoxolone methyl [Dose 3] mg capsules or placebo by mouth once daily x 16 weeks"
            }, 
            {
                "arm_group_label": "Cohort 4: Dose 4", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Bardoxolone methyl [Dose 4] mg capsules or placebo by mouth once daily x 16 weeks"
            }, 
            {
                "arm_group_label": "Cohort 5: Dose 5", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Bardoxolone methyl [Dose 5] mg capsules or placebo by mouth once daily x 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in\n      patients with pulmonary arterial hypertension to determine the recommended dose range and\n      evaluate the change from baseline in 6-minute walk distance (6MWD) following 16 weeks of\n      study participation."
        }, 
        "brief_title": "Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "The molecular and pharmacological effects of bardoxolone methyl are broad through its\n      induction of Nrf2 and suppression of NF-\u03baB. Bardoxolone methyl may therefore address\n      multiple facets of the pathophysiology of PAH because it suppresses activation of\n      proinflammatory mediators, enhances endothelial NO bioavailability, improves metabolic\n      dysfunction, suppresses vascular proliferation, and prevents maladaptive remodeling.\n      Furthermore, while existing therapies primarily target only smooth muscle cells, bardoxolone\n      methyl targets multiple cell types relevant to PAH, including endothelial cells, smooth\n      muscle cells, and macrophages.\n\n      This is a two-part study.\n\n      Part 1: Part 1 of the study will include both dose-escalation and expansion cohorts.\n\n      Part 2 (extension period):  All patients from Part 1 who complete the 16-week treatment\n      period as planned will be eligible to continue directly into the extension period to\n      evaluate the intermediate and long-term safety and efficacy of bardoxolone methyl."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult male and female patients \u2265 18 to \u2264 75 years of age upon study consent;\n\n          2. Symptomatic pulmonary arterial hypertension WHO/NYHA FC class II and III;\n\n          3. One of the following subtypes of WHO Group 1 PAH:\n\n               1. Idiopathic or heritable PAH;\n\n               2. PAH associated with connective tissue disease;\n\n               3. PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1\n                  year following shunt repair;\n\n               4. PAH associated with anorexigens;\n\n               5. PAH associated with human immunodeficiency virus (HIV);\n\n          4. Had a diagnostic right heart catheterization performed and documented within 12\n             months prior to Screening that confirmed a diagnosis of PAH\n\n          5. Has been receiving an oral, disease-specific PAH therapy consisting of an endothelin\n             receptor antagonist (ERA) and/or a phosphodiesterase type-5 inhibitor (PDE5i). PAH\n             therapy must be at a stable dose for at least 90 days prior to Day 1;\n\n          6. Has adequate kidney function defined as an estimated glomerular filtration rate\n             (eGFR) \u2265 60 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD)\n             4-variable formula;\n\n        Exclusion Criteria:\n\n          1. Participation in other interventional clinical studies within 30 days prior to Day 1;\n\n          2. Participation in an intensive exercise training program for pulmonary rehabilitation\n             within 90 days prior to Screening;\n\n          3. Receiving chronic treatment with a prostacyclin/prostacyclin analogue or riociguat\n             within 60 days prior to Day 1. Use of prostacyclin for acute vasodilator testing\n             during right heart catheterization is allowed;\n\n          4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1;\n\n          5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood\n             pressure (BP) > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during\n             Screening after a period of rest;\n\n          6. Has systolic BP < 90 mm Hg during Screening after a period of rest;\n\n          7. Has a history of left-sided heart disease and/or clinically significant cardiac\n             disease,including but not limited to any of the following:\n\n               1. Aortic or mitral valve disease (stenosis or regurgitation) defined as greater\n                  than mild aortic insufficiency;\n\n               2. Pericardial constriction;\n\n               3. Restrictive or congestive cardiomyopathy;\n\n               4. Left ventricular ejection fraction < 40% at the Screen A echocardiogram (ECHO);\n\n               5. Evidence of left ventricular diastolic dysfunction;\n\n               6. Left ventricular shortening fraction < 22% at the Screen A ECHO;\n\n               7. Symptomatic coronary disease;\n\n          8. Acutely decompensated heart failure within 30 days prior to Day 1, as per\n             Investigator assessment;\n\n          9. History of atrial septostomy within 180 days prior to Day 1;\n\n         10. History of obstructive sleep apnea that is untreated;\n\n         11. For patients with HIV-associated PAH, any of the following:\n\n               1. Concomitant active opportunistic infections within 180 days prior to Screening;\n\n               2. Detectable viral load within 90 days prior to Screening;\n\n               3. Cluster designation (CD+) T-cell count < 200 mm3 within 90 days prior to\n                  Screening;\n\n               4. Changes in antiretroviral regimen within 90 days prior to Screening;\n\n               5. Using inhaled pentamidine;\n\n         12. Has a history of portal hypertension or chronic liver disease, including hepatitis B\n             and/or hepatitis C (with evidence of recent infection and/or active virus\n             replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C);\n\n         13. Serum aminotransferase (ALT or AST) levels > the upper limit of normal (ULN) at\n             Screening;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036970", 
            "org_study_id": "RTA 402-C-1302"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1: Dose 1", 
                    "Cohort 2: Dose 2", 
                    "Cohort 3: Dose 3", 
                    "Cohort 4: Dose 4", 
                    "Cohort 5: Dose 5"
                ], 
                "intervention_name": "Bardoxolone methyl", 
                "intervention_type": "Drug", 
                "other_name": "RTA 402 capsules"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1: Dose 1", 
                    "Cohort 2: Dose 2", 
                    "Cohort 3: Dose 3", 
                    "Cohort 4: Dose 4", 
                    "Cohort 5: Dose 5"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pulmonary Arterial Hypertension", 
            "PAH", 
            "Bardoxolone methyl", 
            "6-minute walk distance", 
            "CDDO-me", 
            "RTA 402"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "310-222-3560"
                }, 
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }, 
                    "name": "Harbor - UCLA Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ronald J. Oudiz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "720-848-6540"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Cardiac and Vascular Center"
                }, 
                "investigator": {
                    "last_name": "David Badesch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "303-715-2210"
                }, 
                "facility": {
                    "address": {
                        "city": "Littleton", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80120"
                    }, 
                    "name": "South Denver Cardiology"
                }, 
                "investigator": {
                    "last_name": "Ira Dauber", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "502-587-8000"
                }, 
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "Kentuckian Pulmonary Associates"
                }, 
                "investigator": {
                    "last_name": "John McConnell, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "617-636-1334"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts Medical Center"
                }, 
                "investigator": {
                    "last_name": "Nicholas Hill, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "314-747-8174"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Murali Chakinala, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "513-585-1777"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "Lindner Center for Research & Education at The Christ Hospital"
                }, 
                "investigator": {
                    "last_name": "Peter Engel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "roadst@ucmail.uc.edu", 
                    "last_name": "Research Coordinator"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267"
                    }, 
                    "name": "University of Cincinnati"
                }, 
                "investigator": {
                    "last_name": "Jean Elwing, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mdclifford@health-partners.org", 
                    "last_name": "Research Coordinator"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairfield", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45014"
                    }, 
                    "name": "Mercy Health Physicians Cincinnati, LLC"
                }, 
                "investigator": {
                    "last_name": "Lynne Wagoner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tmayfiel@lhs.org", 
                    "last_name": "Research Coordinator"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Legacy Medical Group - Pulmonary Clinic"
                }, 
                "investigator": {
                    "last_name": "Catherine Markin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "LAKruse@lghealth.org", 
                    "last_name": "Research Coordinator"
                }, 
                "facility": {
                    "address": {
                        "city": "Lancaster", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17603"
                    }, 
                    "name": "The Heart Group of Lancaster General Hospital"
                }, 
                "investigator": {
                    "last_name": "Justin Roberts, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "214-645-6489"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "UT Southwestern Medical Center"
                }, 
                "investigator": {
                    "last_name": "Fernando Torres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Research Coordinator", 
                    "phone": "615-665-7130"
                }, 
                "facility": {
                    "address": {
                        "city": "El Paso", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "79912"
                    }, 
                    "name": "BreatheAmerica El Paso, Inc."
                }, 
                "investigator": {
                    "last_name": "Hernando Garcia, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Arterial Hypertension", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in 6-Minute Walk Distance (6MWD)", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Reata Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reata Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}